Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

NCT01425970 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

210

Enrollment

INDUSTRY

Sponsor class

Stopped Termination of study was due to safety reasons

Conditions

Hepatitis C

Interventions

DRUG: INX-08189
DRUG: INX-08189
DRUG: INX-08189
DRUG: Placebo matching with INX-08189
BIOLOGICAL: Pegylated interferon alfa-2a
DRUG: Ribavirin
DRUG: INX-08189
DRUG: Daclatasvir

Sponsor

Bristol-Myers Squibb